Pain Therapeutics Company Profile (NASDAQ:PTIE)

Analyst Ratings

Consensus Ratings for Pain Therapeutics (NASDAQ:PTIE) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Pain Therapeutics (NASDAQ:PTIE)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Pain Therapeutics (NASDAQ:PTIE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/21/2016        
7/19/2016Q216($0.14)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2016Q1($0.10)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2014Q314($0.08)$89.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q214($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q1 14($0.06)($0.08)$1.96 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2014Q413($0.01)$0.72$2.00 million$35.24 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313($0.01)($0.02)$2.00 million$1.96 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2013Q1 2013($0.01)($0.01)$2.80 million$1.96 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2013Q4 2012($0.02)($0.08)$2.79 million$2.47 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Pain Therapeutics (NASDAQ:PTIE)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Pain Therapeutics (NASDAQ:PTIE)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
12/11/2012special$0.7512/13/201212/17/201212/24/2012Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Pain Therapeutics (NASDAQ:PTIE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/6/2013Sanford RobertsonDirectorBuy50,000$3.73$186,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Pain Therapeutics (NASDAQ:PTIE)
DateHeadline
07/22/16 07:45 AMPain Therapeutics (PTIE) Worth a Look: Stock Gains 7.6% -
07/20/16 06:50 PMPain Therapeutics net loss improves by 12% in Q2
07/20/16 08:48 AMPain Therapeutics (PTIE) Reports Q2 Loss of $0.07/Share
07/19/16 06:06 PMPain Therapeutics Reports Q2 2016 Financial Results
07/19/16 04:07 PMPain Therapeutics reports 2Q loss -
07/12/16 10:21 AMTop 3 Biotech Companies Awaiting FDA Approval (PTIE,DRRX,PGNX)
07/07/16 08:48 AMStocks Gapping Down Today – CAPR, SBSA, NBN, VRAY, SKIS, PTI, OXFD
07/06/16 10:36 AMNear Term Approval of Durect (DRRX) REMOXY Likely as FDA Panel Deemed Unnecessary - Rodman & Renshaw
07/05/16 11:46 AMIs Pain Therapeutics, Inc. (PTIE) And Remoxy’s Long And Winding Road Nearing An End? -
07/04/16 05:09 PMIs Pain Therapeutics, Inc. (NASDAQ:PTIE) And Remoxy’s Long And Winding Road Nearing An End?
07/01/16 08:21 AMPain Therapeutics Announces Advisory Committee Meeting for REMOXY® Is Not Needed - [at noodls] - No Change to September 25th PDUFA Date AUSTIN, Texas, July 01, 2016 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that the U.S. Food and Drug Administration (FDA) has determined ...
06/29/16 03:11 PMPAIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers -
06/08/16 05:05 PMPain Therapeutics, Inc. :PTIE-US: Earnings Analysis: Q1, 2016 By the Numbers : June 8, 2016 -
05/29/16 09:07 PMPain Therapeutics Incorporated (NASDAQ:PTIE) Short Interest Increased By 43.28% - HNN - Pain Therapeutics Incorporated (NASDAQ:PTIE) Short Interest Increased By 43.28%HNNThe short interest to Pain Therapeutics Incorporated's float is 2.28%. The stock increased 0.87% or $0.02 on May 27, hitting $2.32. About 27,301 shares traded hands. Pain Therapeutics, Inc. (NASDAQ:PTIE) has risen 26.78% since October 22, 2015 and is ...and more »
05/20/16 04:05 PMPain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY® - Investing News Network (press release) (registration) (blog) - Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY®Investing News Network (press release) (registration) (blog)AUSTIN, Texas, May 19, 2016 (GLOBE NEWSWIRE) — Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that an Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the REMOXY® New Drug Application (NDA), tentatively ...DURECT Announces FDA Advisory Committee Meeting for REMOXY®SYS-CON Media (press release)all 3 news articles »
05/19/16 04:08 PMPain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY® - GlobeNewswire (press release) - Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY®GlobeNewswire (press release)AUSTIN, Texas, May 19, 2016 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that an Advisory Committee of the U.S. Food and Drug Administration (FDA) will review the REMOXY® New Drug Application (NDA), tentatively ...Pain Therapeutics Says FDA Advisory Committee to Review Pain Drug Remoxy on August 5 (NASDAQ:PTIE)Sonoran Weekly ReviewDURECT Announces FDA Advisory Committee Meeting for REMOXY®SYS-CON Media (press release)all 3 news articles »
05/19/16 08:12 AMPain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY® - [at noodls] - - August 5 is FDA's Tentative Date for Advisory Committee Meeting - - No Change to PDUFA Date - AUSTIN, Texas, May 19, 2016 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) announced today that ...
05/19/16 08:05 AMDURECT Announces FDA Advisory Committee Meeting for REMOXY® - [PR Newswire] - REMOXY, an investigational drug, is a unique long-acting oral formulation of oxycodone intended to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Based on DURECT's ORADUR® technology, which is covered by issued patents and pending patent applications owned by us, REMOXY is designed to discourage common methods of tampering associated with prescription opioid analgesic misuse and abuse. The FDA has accepted for review the NDA for REMOXY. The REMOXY NDA has a PDUFA target date of September 25, 2016. In December 2002, DURECT licensed to Pain Therapeutics the right to develop and commercialize on a worldwide basis REMOXY and other oral sustained release drug candidates that use the ORADUR technology and incorporate certain specified opioid compounds.
05/17/16 07:53 AMPain Therapeutics Incorporated (NASDAQ:PTIE) Sellers Increased By 13.84% Their Shorts - Wall Street Hints and News - Pain Therapeutics Incorporated (NASDAQ:PTIE) Sellers Increased By 13.84% Their ShortsWall Street Hints and NewsThe short interest to Pain Therapeutics Incorporated's float is 1.86%. The stock increased 1.67% or $0.04 on May 16, hitting $2.43. About 40,391 shares traded hands. Pain Therapeutics, Inc. (NASDAQ:PTIE) has risen 22.11% since October 9, 2015 and is ...and more »
05/16/16 09:05 AMHC Stocks Judgment: Rosetta Genomics Ltd. (ROSG), Pain Therapeutics Inc. (PTIE), MediciNova Inc. (MNOV) - share market updates (press release) - share market updates (press release)HC Stocks Judgment: Rosetta Genomics Ltd. (ROSG), Pain Therapeutics Inc. (PTIE), MediciNova Inc. (MNOV)share market updates (press release)Shares of Rosetta Genomics Ltd. (USA) (NASDAQ:ROSG) ended Friday session in red amid volatile trading. The shares closed down -0.03 points or -2.61% at $1.12 with 53.786.00 shares getting traded. Post opening the session at $1.12, the shares hit an ...and more »
05/12/16 03:48 PMPAIN THERAPEUTICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/11/16 04:33 PMPain Therapeutics to Present New REMOXY Data At American Pain Society Meeting - Nasdaq - Pain Therapeutics to Present New REMOXY Data At American Pain Society MeetingNasdaqAUSTIN, Texas, May 11, 2016 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced that researchers will present new data around REMOXY's abuse-deterrent properties at the 35th Annual Scientific Meeting of the American Pain ...and more »
05/11/16 08:05 AMPain Therapeutics to Present New REMOXY Data At American Pain Society Meeting - [GlobeNewswire] - AUSTIN, Texas, May 11, 2016-- Pain Therapeutics, Inc. today announced that researchers will present new data around REMOXY’ s abuse-deterrent properties at the 35 th Annual Scientific Meeting of the American ...
05/11/16 08:05 AMDURECT Announces New REMOXY® Data being Presented at American Pain Society Meeting - [PR Newswire] - CUPERTINO, Calif., May 11, 2016 /PRNewswire/ -- DURECT Corporation (DRRX) today announced researchers will present new data around REMOXY's abuse-deterrent properties at the 35th Annual Scientific Meeting of the American Pain Society (APS) meeting. The scientific poster is titled "REMOXY: Human Abuse Potential Study of an Extended-Release Oxycodone Formulation." Co-authors Lynn Webster and Nadav Friedmann are scheduled to present the data at APS on Thursday, May 12, 2016, from 3:45 to 5:15 pm Central Time. This scientific poster will be available for review by the general public on DURECT's website at www.durect.com. REMOXY, an investigational drug, is a unique long-acting oral formulation of oxycodone intended to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Based on DURECT's ORADUR® technology, which is covered by issued patents and pending patent applications owned by us, REMOXY is designed to discourage common methods of tampering associated with prescription opioid analgesic misuse and abuse. The U.S. Food and Drug Administration (FDA) has accepted for review the new drug application (NDA) for REMOXY. The REMOXY NDA has a Prescription Drug User Fee Act (PDUFA) target date of September 25, 2016.
05/06/16 10:50 AMDRRX: Update on First Quarter Financials -
05/05/16 09:46 PMPain Therapeutics (PTIE) Drops 6.45% on May 04 - Equities.com - Pain Therapeutics (PTIE) Drops 6.45% on May 04Equities.comPain Therapeutics (PTIE) was one of the Russell 2000's biggest losers for Wednesday May 04 as the stock slid 6.45% to $2.32, a loss of $-0.16 per share. Starting at an ... Pain Therapeutics Inc is a biopharmaceutical company that develops novel drugs.and more »
05/05/16 09:46 PMPain Therapeutics Reports Q1 2016 Financial Results - GlobeNewswire (press release) - Pain Therapeutics Reports Q1 2016 Financial ResultsGlobeNewswire (press release)AUSTIN, Texas , May 05, 2016 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the first quarter of 2016. Net loss in Q1 2016 was $5.8 million, or $0.13 per share, compared to a net loss in Q1 2015 of $2.6 ...and more »
05/05/16 06:01 PMPain Therapeutics reports 1Q loss -
05/05/16 03:21 PMPain Therapeutics Reports Q1 2016 Financial Results - [at noodls] - AUSTIN, Texas , May 05, 2016 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today reported financial results for the first quarter of 2016. Net loss in Q1 2016 was $5.8 million, or $0.13 per ...
05/05/16 03:10 PMPAIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -
04/25/16 05:16 PMPain Therapeutics, Inc. (NASDAQ:PTIE)'s Company Shares Increased 19.51% After High Volatility - B.O.D.Y Confidential - Pain Therapeutics, Inc. (NASDAQ:PTIE)'s Company Shares Increased 19.51% After High VolatilityB.O.D.Y ConfidentialThe shares of Pain Therapeutics, Inc. (NASDAQ:PTIE) increased by 19.51% in the last 20 days and rose 2.51% in the past 5 trading sessions. Pain Therapeutics, Inc. (NASDAQ:PTIE) shares opened at $2.35 in the last session and had intraday high of $2.50 ...Worth Watching Stocks: Fidelity Southern Corporation (NASDAQ:LION), Pain Therapeutics Inc. (NASDAQ:PTIE), Care ...Stock TranscriptTickers Trending: Ally Financial Inc. (NYSE:ALLY), ServiceNow (NYSE:NOW), Fastenal Company (NASDAQ:FAST ...Property Mentorall 3 news articles »
04/25/16 05:16 PMMarket Movers: Alcoa Inc. (NYSE:AA), Pain Therapeutics Inc. (NASDAQ:PTIE), First Commonwealth Financial Corp ... - KC Register - Market Movers: Alcoa Inc. (NYSE:AA), Pain Therapeutics Inc. (NASDAQ:PTIE), First Commonwealth Financial Corp ...KC RegisterOn 12 April, Pain Therapeutics Inc. (NASDAQ:PTIE) announced that the U.S. Food and Drug Administration (FDA) has determined that the New Drug Application (NDA) resubmission for REMOXY®, an abuse-deterrent formulation of extended-release ...
04/24/16 02:33 AMWhat's Ahead for Pain Therapeutics, Inc. After Today's Huge Increase? - The Post - Mas Market NewsWhat's Ahead for Pain Therapeutics, Inc. After Today's Huge Increase?The PostThe stock of Pain Therapeutics, Inc. (NASDAQ:PTIE) is a huge mover today! The stock increased 5.10% or $0.12 on April 22, hitting $2.45. About 251,549 shares traded hands or 89.48% up from the average. Pain Therapeutics, Inc. (NASDAQ:PTIE) has risen ...Pain Therapeutics (PTIE) Jumps 5.1% on April 22Equities.comPain Therapeutics Incorporated (NASDAQ:PTIE) Shorted Shares Increased 0.99% After Market SellingFranklin Independentall 7 news articles »
04/22/16 09:47 PMPain Therapeutics (PTIE) Jumps 5.1% on April 22 - Equities.com - Pain Therapeutics (PTIE) Jumps 5.1% on April 22Equities.comPain Therapeutics (PTIE) was among the biggest gainers on the Russell 2000 for Friday April 22 as the stock popped 5.1% to $2.45, representing a gain of $0.1189 per share. Some 251,549 shares traded hands on 576 trades, compared with an average ...Pain Therapeutics Incorporated (NASDAQ:PTIE) Shorted Shares Increased 0.99% After Market SellingFranklin Independentall 2 news articles »
04/22/16 04:41 PMStocks Roundup: Silver Standard Resources (SSRI), Pain Therapeutics (PTIE), Cymabay Therapeutics (CBAY) - iStreetWire - Stocks Roundup: Silver Standard Resources (SSRI), Pain Therapeutics (PTIE), Cymabay Therapeutics (CBAY)iStreetWirePain Therapeutics Inc. (PTIE) grew with the stock adding 4.39% or $0.1 to close at $2.33 on light trading volume of 1.01M compared its three months average trading volume of 80.43K. The Austin Texas 78731 based company operating under the ...and more »
04/22/16 04:41 PMStocks Roundup: Pain Therapeutics Inc. (PTIE), Cymabay Therapeutics, Inc. (CBAY), Silver Standard Resources Inc ... - iStreetWire - Stocks Roundup: Pain Therapeutics Inc. (PTIE), Cymabay Therapeutics, Inc. (CBAY), Silver Standard Resources Inc ...iStreetWirePain Therapeutics Inc. (PTIE) grew with the stock adding 4.39% or $0.1 to close at $2.33 on light trading volume of 1.01M compared its three months average trading volume of 80.43K. The Austin Texas 78731 based company operating under the ...
04/13/16 04:37 PM10 Stocks Moving In Wednesday's Pre-Market Session - Benzinga - 10 Stocks Moving In Wednesday's Pre-Market SessionBenzingaPain Therapeutics, Inc. (NASDAQ: PTIE) rose 18.48 percent to $2.50 in pre-market trading on news the FDA had accepted REMOXY's New Drug Application (NDA) for review, setting a PDUFA date of September 25, 2016. Arrowhead Pharmaceuticals Inc ...and more »
04/13/16 04:37 PMPain Therapeutics Gains 7%, FDA Has Accepted Company's Remoxy For Review - Benzinga - Equities.comPain Therapeutics Gains 7%, FDA Has Accepted Company's Remoxy For ReviewBenzingaShares of Pain Therapeutics, Inc. PTIE 7.62%, a micro-cap biopharmaceutical company whose lead drug candidate, REMOXY, is used for the treatment of moderate to severe pain. Pain Therapeutics announced after Tuesday's market close the U.S. Food and ...Will Pain Therapeutics, Inc. Go Down Anytime Soon?Business Standard TribuneZacks: Pain Therapeutics, Inc. (NASDAQ:PTIE) Receives Average Rating of "Strong Buy" from AnalystsWeb Breaking NewsDurect, Pain Therapeutics Gain as FDA Accepts REMOXY New Drug Application (NASDAQ:DRRX)Sonoran Weekly ReviewEquities.comall 7 news articles »
04/13/16 04:37 PMDrug Pricing, Presidential Politics, and Three Biotechs with Promise - The president and presidential candidates have been discussing the epidemic of opioid abuse and addiction in the U.S. I'd like to talk about Pain Therapeutics Inc. (PTIE:NASDAQ). Not only is this company addressing this important issue, but the name is ...
04/13/16 04:37 PMPain Therapeutics (PTIE) Gains on FDA Nod - Pain Therapeutics, Inc. (NASDAQ: PTIE) rose 5.7% to $2.22 on news the FDA had accepted REMOXY’s New Drug Application (NDA) for review, setting a PDUFA date of September 25. Share volume was 240,000, compared to an all-day average of 85,000
04/13/16 11:38 AMPain Therapeutics Gains 7%, FDA Has Accepted Company's Remoxy For Review - Shares of Pain Therapeutics, Inc. (NASDAQ: PTIE), a micro-cap biopharmaceutical company whose lead drug candidate, REMOXY, is used for the treatment of moderate to severe pain. Pain Therapeutics announced after Tuesday's market close the U.S. Food and Drug Administration determined that its ...Full story available on Benzinga.com
04/12/16 09:43 PMPain Therapeutics (PTIE) Announces FDA Acceptance of REMOXY NDA Resubmission - Pain Therapeutics, Inc. (Nasdaq: PTIE) announced that the U.S. Food and Drug Administration (FDA) has determined that the New Drug Application (NDA) resubmission for REMOXY®, an abuse-deterrent formulation of extended-release oxycodone (CII) capsules ...
04/12/16 05:34 PMDURECT Announces FDA Acceptance of REMOXY® NDA, PDUFA Date of September 25, 2016 - [PR Newswire] - REMOXY, an investigational drug, is a unique long-acting oral formulation of oxycodone intended to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Based on DURECT's ORADUR® technology, which is covered by issued patents and pending patent applications owned by us, REMOXY is designed to discourage common methods of tampering associated with prescription opioid analgesic misuse and abuse. In December 2002, DURECT licensed to Pain Therapeutics the right to develop and commercialize on a worldwide basis REMOXY and other oral sustained release drug candidates that use the ORADUR technology and incorporate certain specified opioid compounds.
04/12/16 04:39 PMPain Therapeutics (PTIE) Announces FDA Acceptance of REMOXY NDA Resubmission - StreetInsider.com - Pain Therapeutics (PTIE) Announces FDA Acceptance of REMOXY NDA ResubmissionStreetInsider.comPain Therapeutics, Inc. (Nasdaq: PTIE) announced that the U.S. Food and Drug Administration (FDA) has determined that the New Drug Application (NDA) resubmission for REMOXY®, an abuse-deterrent formulation of extended-release oxycodone (CII) ...and more »
04/12/16 03:26 PMFDA Accepts REMOXY NDA for Review, Sets PDUFA Date of September 25, 2016 - [at noodls] - - Company Will Host Conference Call on Wednesday, April 13, 8:30am EDT - - Guest Speaker Invited to Discuss REMOXY's Target Market - AUSTIN, Texas, April 12, 2016 (GLOBE NEWSWIRE) -- Pain Therapeutics, ...
04/11/16 04:29 PMInstitutional Investors Are Selling Pain Therapeutics Inc (NASDAQ:PTIE) - Clinton Financial - Institutional Investors Are Selling Pain Therapeutics Inc (NASDAQ:PTIE)Clinton FinancialPain Therapeutics Inc (NASDAQ:PTIE) institutional sentiment increased to 0.83 in 2015 Q3. Its up 0.49, from 0.34 in 2015Q2. The ratio is more positive, as 13 investment managers opened new or increased positions, while 38 cut down and sold stakes in ...and more »
04/09/16 02:57 AMPain Therapeutics Incorporated (NASDAQ:PTIE) Sellers Increased By 5.51% Their Shorts - Stock Caller - Pain Therapeutics Incorporated (NASDAQ:PTIE) Sellers Increased By 5.51% Their ShortsStock CallerThe short interest to Pain Therapeutics Incorporated's float is 2.27%. The stock increased 0.47% or $0.01 on April 8, hitting $2.16. About 71,717 shares traded hands. Pain Therapeutics, Inc. (NASDAQ:PTIE) has risen 19.34% since September 2, 2015 and is ...and more »
04/07/16 04:52 PMBvf Incil buys $3.9 Million stake in Pain Therapeutics (PTIE) - SCSUCollegian - Bvf Incil buys $3.9 Million stake in Pain Therapeutics (PTIE)SCSUCollegianOther Hedge Funds, Including , Geode Capital Management boosted its stake in PTIE during the Q4 period, The investment management firm added 348 additional shares and now holds a total of 203,457 shares of Pain Therapeutics which is valued at $425,225 ...and more »
04/04/16 04:33 PMPain Therapeutics Incorporated (NASDAQ:PTIE) Short Interest Increased By 5.51% - Stock Caller - Pain Therapeutics Incorporated (NASDAQ:PTIE) Short Interest Increased By 5.51%Stock CallerThe short interest to Pain Therapeutics Incorporated's float is 2.27%. The stock is down 1.55% or $0.03 after the news, hitting $2.18 per share. About 96,398 shares traded hands or 12.73% up from the average. Pain Therapeutics, Inc. (NASDAQ:PTIE) has ...and more »
04/03/16 09:12 PMCompany Shares of Pain Therapeutics (NASDAQ:PTIE) Rally 7.8% - SCSUCollegian - Company Shares of Pain Therapeutics (NASDAQ:PTIE) Rally 7.8%SCSUCollegianPain Therapeutics (NASDAQ:PTIE) has climbed 7.8% in the past week and advanced 11.06% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 5.89% and the outperformance has advanced to 7.16% for the last 4 weeks ...

Social

About Pain Therapeutics

Pain Therapeutics logoPain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. The Company has developed REMOXY to make oxycodone difficult to abuse yet provide approximately 12 hours of steady pain relief when used by patients. REMOXY is intended to meet the needs of healthcare prescribing opioid drugs and seeking to minimize the risks of drug diversion, abuse or accidental patient misuse. The Company's drug candidate FENROCK is an abuse-deterrent transdermal pain patch in the pre-Investigational new drug-stage of development. FENROCK is designed to provide pain relief over 72 hours.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: PTIE
  • CUSIP: 69562K10
Key Metrics:
  • Previous Close: $2.71
  • 50 Day Moving Average: $2.2257
  • 200 Day Moving Average: $2.1099
  • P/E Ratio: N/A
  • P/E Growth: -0.0600
  • Market Cap: $123.82M
  • Beta: 1.05
  • Current Year EPS Consensus Estimate: $-0.54 EPS
  • Next Year EPS Consensus Estimate: $-0.52 EPS
Additional Links:
Pain Therapeutics (NASDAQ:PTIE) Chart for Thursday, July, 28, 2016